ALLERGOLOGIE is a prominent academic journal dedicated to the field of immunology and allergy, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany. Since its inception in 1978, the journal has provided a vital platform for researchers, clinicians, and students to disseminate their findings, share insights, and foster advancements in the understanding of allergic diseases and immunological responses. With an ISSN of 0344-5062 and an E-ISSN of the same number, it is a respected source within its category, currently ranked in the 2023 Q4 of the Scopus metrics in immunology and allergy, reflecting its commitment to quality and scholarly rigor. Although not fully open access, ALLERGOLOGIE makes significant contributions to the dialogue on allergy-related topics, encouraging engagement from its readership through a diverse array of articles that span from clinical trials to innovative research methods. This journal continues to be an essential resource for anyone involved in the pursuit of knowledge in allergy and immunology.

Postepy Dermatologii i Alergologii is a distinguished Open Access journal published by TERMEDIA PUBLISHING HOUSE LTD, dedicated to advancing the fields of Dermatology and Immunology and Allergy. Since its inception in 2003, this journal has served as a vital platform for researchers and practitioners alike, promoting knowledge sharing and collaboration in Poland and beyond. With a current impact ranking placing it in the Q3 quartile for both Dermatology and Immunology and Allergy categories, it plays a significant role in contributing to academic discourse within these fields. The journal is indexed in Scopus, with respectable rankings reflecting its relevance and quality—#65/142 in Dermatology and #163/233 in Immunology and Allergy. Researchers are encouraged to explore a vast array of innovative studies and reviews, making it an essential resource for anyone seeking to stay at the forefront of dermatological and allergic research. For those interested in discovering groundbreaking findings and contributing to the ongoing dialogue in these disciplines, Postepy Dermatologii i Alergologii offers not only free accessibility but also a commitment to scholarly excellence.

ALLERGOLOGIA ET IMMUNOPATHOLOGIA is a distinguished academic journal dedicated to the field of immunology and allergy, published by CODON PUBLICATIONS, based in Singapore. With its ISSN 0301-0546 and E-ISSN 1578-1267, this journal aims to provide an open platform for researchers and practitioners to share their findings, emphasizing topics related to immunopathology and respiratory health. Covering a broad scope from 1973 to 2024, it currently holds a notable position in several category quartiles, including Q3 in Immunology and Allergy, and Q3 in Pulmonary and Respiratory Medicine as of 2023. Despite the absence of an open access option, the journal maintains an essential role in disseminating pivotal research, reflected in its Scopus rankings that position it within the core of its discipline. With an impact factor acknowledging the significance of its contributions, ALLERGOLOGIA ET IMMUNOPATHOLOGIA continues to be a vital resource for ongoing education and advancement in immunological and allergic research.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

Asia Pacific Allergy, published by Lippincott Williams & Wilkins, is a prominent academic journal dedicated to advancing research and clinical practice in the fields of dermatology, immunology, and allergy. With its ISSN 2233-8276 and E-ISSN 2233-8268, the journal provides a platform for innovative studies and reviews that cater to an international audience of researchers, healthcare professionals, and students involved in allergy and related disorders. Although it does not currently offer open access to its publications, the journal's robust output from 2015 to 2017 and its ongoing contribution to the literature from 2021 to 2024 showcase the evolving landscape of allergy research in the Asia Pacific region. Recognized in the 2023 Journal Citation Reports, it holds a Q2 ranking in Dermatology and a Q3 ranking in Immunology and Allergy, while its Scopus ranks further emphasize its significance within these domains, positioning it among the top journals in the field. As a source of cutting-edge research, Asia Pacific Allergy plays a vital role in fostering collaboration and knowledge dissemination, ultimately assisting in the betterment of patient care and treatment strategies across the region.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, published by KARGER, is a distinguished journal dedicated to advancing the field of immunology and allergy research. With an ISSN of 1018-2438 and an E-ISSN of 1423-0097, this journal has been a vital resource since its inception in 1950, continuing to publish influential articles through 2024. Hailing from Switzerland, it holds an important position within the Q3 category in Immunology and Allergy and Q2 in miscellaneous Medicine, reflecting its growing impact in the scientific community. The Scopus rankings showcase its relevance, with a 52nd percentile in Immunology and Allergy and 45th in Immunology and Microbiology. Although not an open-access journal, it plays a critical role in disseminating significant findings and innovations in the understanding of allergic diseases and immunological responses. The INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY is essential for researchers, clinicians, and students eager to stay at the forefront of allergy and immunology developments.

ALLERGY AND ASTHMA PROCEEDINGS, published by Ocean Side Publications Inc, is a vital resource in the fields of Immunology, Allergy, and Pulmonary Medicine. With an impressive trajectory of publication from 1996 to 2024, this journal serves as a platform for cutting-edge research and advancements in the understanding of allergic and asthmatic conditions. Positioned in the Q3 quartile for Immunology and Allergy and Q2 for both Medicine (miscellaneous) and Pulmonary Medicine, the journal exhibits a robust impact within the academic community, boasting Scopus rankings that reflect its significance. The journal offers open access options, allowing for the dissemination of critical findings to a wider audience. Aimed at researchers, healthcare professionals, and students alike, ALLERGY AND ASTHMA PROCEEDINGS addresses the complexities of respiratory diseases and facilitates the sharing of knowledge that is essential to improving patient care and outcomes.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, focusing on the dynamic fields of immunology and allergy. With an ISSN of 0889-8561 and an E-ISSN of 1557-8607, this journal has consistently ranked in the Q2 category in both Immunology and Immunology and Allergy as per 2023 metrics, underscoring its critical role in academia. It provides cutting-edge research, comprehensive reviews, and practical insights that cater to the needs of researchers, clinicians, and students alike. Though the journal is not open access, it remains an essential resource for those involved in advancing knowledge and clinical practice in allergy and immunology. With its converged years stretching from 1987 to 2024, the journal serves as a rich repository of scientific advancements, fostering progress in diagnosis, treatment, and prevention of allergic diseases and immune disorders. Positioned within the United States and based in Philadelphia, it plays a vital role in promoting scholarly communication within these impactful fields.

Welcome to the Allergo Journal, a pivotal publication in the field of Immunology and Allergy, housed under the esteemed SPRINGER HEIDELBERG publishing house. With an ISSN of 0941-8849 and E-ISSN 2195-6405, the journal has been serving the scientific community since its inception in 1994. Although its Scopus coverage was discontinued in 2017, the journal remains significant, ranked #135 out of 186 in its category and positioned in the 27th percentile, reflecting its contributions to vital research in allergy and immunological disorders. While the journal is not an open access publication, it continues to provide a platform for rigorous academic discourse and advances in the study of allergens and immune response. The Allergo Journal stands as a crucial resource for researchers, professionals, and students dedicated to deepening their understanding of allergies and immunology, fostering advancements in therapy and comprehensive patient care.

Current Treatment Options in Allergy is an esteemed academic journal published by SpringerNature, focusing on a critical area of health science: the evolving landscape of allergy treatments. With an E-ISSN of 2196-3053, this journal aims to provide a comprehensive platform for researchers and practitioners in the fields of Immunology and Allergy and Medicine. It has garnered recognition in the academic community, reflecting its significant contribution with a Q3 ranking in Immunology and Allergy and a Q3 ranking in Medicine as of 2023. The journal is based in Switzerland and encompasses research spanning from 2014 to 2024, ensuring that the latest findings and treatment options are available to professionals and students alike. With a growing focus on open access, it aims to make critical allergy treatment research widely accessible, thus fostering innovation and collaboration in this vital health sector. As the prevalence of allergies continues to rise globally, Current Treatment Options in Allergy plays a crucial role in disseminating important research and treatment strategies to improve patient outcomes.